JP2006516594A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006516594A5 JP2006516594A5 JP2006501920A JP2006501920A JP2006516594A5 JP 2006516594 A5 JP2006516594 A5 JP 2006516594A5 JP 2006501920 A JP2006501920 A JP 2006501920A JP 2006501920 A JP2006501920 A JP 2006501920A JP 2006516594 A5 JP2006516594 A5 JP 2006516594A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- inflammatory disorder
- disorder
- pharmaceutical composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 200000000018 inflammatory disease Diseases 0.000 claims 14
- 201000010099 disease Diseases 0.000 claims 13
- 210000003169 Central Nervous System Anatomy 0.000 claims 10
- 206010024381 Leukodystrophy Diseases 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 101710023772 SEMA4D Proteins 0.000 claims 6
- 102100001289 SEMA4D Human genes 0.000 claims 6
- 210000001428 Peripheral Nervous System Anatomy 0.000 claims 4
- 230000001919 adrenal Effects 0.000 claims 4
- 102000004965 antibodies Human genes 0.000 claims 4
- 108090001123 antibodies Proteins 0.000 claims 4
- 108010056102 CD100 antigen Proteins 0.000 claims 3
- 206010068202 Leukodystrophy Diseases 0.000 claims 3
- 102100017923 ACOT12 Human genes 0.000 claims 2
- 101710008266 ACOT12 Proteins 0.000 claims 2
- 102100001910 ASPA Human genes 0.000 claims 2
- 101700019344 ASPA Proteins 0.000 claims 2
- 210000004100 Adrenal Glands Anatomy 0.000 claims 2
- 201000000013 Alexander disease Diseases 0.000 claims 2
- 206010067608 Canavan disease Diseases 0.000 claims 2
- 208000002183 Guillain-Barre Syndrome Diseases 0.000 claims 2
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 claims 2
- 206010028570 Myelopathy Diseases 0.000 claims 2
- 206010029331 Neuropathy peripheral Diseases 0.000 claims 2
- 210000004248 Oligodendroglia Anatomy 0.000 claims 2
- 102100004920 PEX7 Human genes 0.000 claims 2
- 108060006186 PHYH Proteins 0.000 claims 2
- 206010061928 Radiculitis Diseases 0.000 claims 2
- 208000005587 Refsum Disease Diseases 0.000 claims 2
- 206010061367 Spinal cord disease Diseases 0.000 claims 2
- 201000004525 Zellweger syndrome Diseases 0.000 claims 2
- 238000004166 bioassay Methods 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 210000004027 cells Anatomy 0.000 claims 2
- 108091006028 chimera Proteins 0.000 claims 2
- 201000001996 leukoencephalopathy with vanishing white matter Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000002093 peripheral Effects 0.000 claims 2
- 230000001568 sexual Effects 0.000 claims 2
- 238000002965 ELISA Methods 0.000 claims 1
- 108050003978 Semaphorin Proteins 0.000 claims 1
- 102000014105 Semaphorin Human genes 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 238000003018 immunoassay Methods 0.000 claims 1
- 238000000099 in vitro assay Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000004393 prognosis Methods 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
- 210000004885 white matter Anatomy 0.000 claims 1
Claims (16)
- BD16及び／もしくはBB18抗-CD100抗体、又はそれらのキメラ型もしくはヒト型、又はBD16もしくはBB18に類似の又は密接に関連するエピトープ(類）を認識するヒト抗-CD100抗体、又はそれらの断片を含む、中枢神経系(CNS)又は抹消神経系(PNS)炎症性疾患の予防又は治療のための医薬組成物。
- 前記炎症性障害が、希突起膠細胞に影響を与えるミエリン障害又は疾患である、請求項１記載の医薬組成物。
- 前記炎症性障害が、有髄末梢細胞に影響を与える疾患である、請求項１記載の医薬組成物。
- 前記CNS炎症性障害が、多発性硬化症である、請求項２記載の医薬組成物。
- 前記CNS炎症性障害が、HTLV-1関連脊髄症である、請求項２記載の医薬組成物。
- 前記炎症性障害が、末梢神経系の中枢の外傷後ミエリン障害である、請求項１記載の医薬組成物。
- 前記炎症性障害が、乏渇感症、ロイコジストロフィ、ギラン・バレー症候群、アレクサンダー病、カナバン病、クラッペ病、ペリツェウス・メルツバッハー病、ツェルウェガー病、レフサム病、CACH病、X -関連副腎性白質ジストロフィ、副腎性白質ジストロフィ、副腎脊髄神経障害、未知起源のロイコジストロフィ、及び多発性神経根炎からなる群より選ばれる、請求項１記載の医薬組成物。
- 対照対象の生物試料中のCD100セマフォリンのレベルと比較して、試験対象の生物試料中のCD100セマフォリンを測定することを含むin vitro検定方法であって、
ここで、CD100の高レベルが前記障害又は低予後の指標であり、当該検定がBD16及び／もしくはBB18抗-CD100抗体、それらのキメラ型もしくはヒト型、又はBD16もしくはBB18に類似の又は密接に関連するエピトープ(類）を認識するヒト抗-CD100抗体、又はそれらの断片を用いる免疫学的検定であり、
当該検定の結果が、中枢神経系(CNS)又は末梢神経系(PNS)炎症障害の発症の診断又は決定のために用いられる、前記方法。 - 前記炎症性障害が、希突起膠細胞に影響を与えるミエリン障害又は疾患である、請求項８記載の方法。
- 前記炎症性障害が、有髄末梢細胞に影響を与える疾患である、請求項８記載の方法。
- 前記CNS炎症性障害が、多発性硬化症である、請求項９記載の方法。
- 前記CNS炎症性障害が、HTLV-1関連脊髄症である、請求項９記載の方法。
- 前記炎症性障害が、末梢神経系の中枢の外傷後ミエリン障害である、請求項８記載の方法。
- 前記炎症性障害が、乏渇感症、ロイコジストロフィ、ギラン・バレー症候群、アレクサンダー病、カナバン病、クラッペ病、ペリツェウス・メルツバッハー病、ツェルウェガー病、レフサム病、CACH病、X-関連副腎性白質ジストロフィ、副腎性白質ジストロフィ、副腎脊髄神経障害、未知起源のロイコジストロフィ、及び多発性神経根炎からなる群より選ばれる、請求項８記載の方法。
- 前記CD100セマフォリンが、ELISA法の手段によって検定される、請求項８記載の方法。
- 前記CD100セマフォリンが、CSF試料を使って検定される、請求項１５記載の方法。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03290247.0 | 2003-01-31 | ||
| EP03290247A EP1442749A1 (en) | 2003-01-31 | 2003-01-31 | Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system |
| PCT/EP2004/001743 WO2004067034A1 (en) | 2003-01-31 | 2004-02-02 | Use of anti-cd100 antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006516594A JP2006516594A (ja) | 2006-07-06 |
| JP2006516594A5 true JP2006516594A5 (ja) | 2007-01-18 |
| JP4768597B2 JP4768597B2 (ja) | 2011-09-07 |
Family
ID=32605433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006501920A Expired - Fee Related JP4768597B2 (ja) | 2003-01-31 | 2004-02-02 | 抗−ｃｄ１００抗体の使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8067247B2 (ja) |
| EP (2) | EP1442749A1 (ja) |
| JP (1) | JP4768597B2 (ja) |
| BR (1) | BRPI0406689A (ja) |
| CA (1) | CA2514226C (ja) |
| CY (1) | CY1112953T1 (ja) |
| DK (1) | DK1587542T3 (ja) |
| ES (1) | ES2388735T3 (ja) |
| PT (1) | PT1587542E (ja) |
| SI (1) | SI1587542T1 (ja) |
| WO (1) | WO2004067034A1 (ja) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7150286B2 (ja) | 2018-07-19 | 2022-10-11 | 国立大学法人 東京大学 | Ｈｔｌｖ－１関連脊髄症（ｈａｍ）治療又は予防剤、及びｈａｍの治療方法 |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6576754B2 (en) * | 1995-11-09 | 2003-06-10 | Dana-Farber Cancer Institute | CD100 antigen and uses therefor |
| EP1442749A1 (en) * | 2003-01-31 | 2004-08-04 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system |
| ATE494306T1 (de) * | 2007-02-14 | 2011-01-15 | Vaccinex Inc | Humanisierte anti-cd100-antikörper |
| ES2647823T3 (es) | 2009-05-08 | 2017-12-26 | Vaccinex, Inc. | Anticuerpos anti-CD100 y métodos de uso de los mismos |
| EP2487242A1 (en) * | 2011-02-09 | 2012-08-15 | Ruprecht-Karls-Universität Heidelberg | B-type plexin antagonists and uses thereof |
| ES2640567T3 (es) | 2011-05-13 | 2017-11-03 | National University Corporation Tokyo Medical And Dental University | Promotor de la osteogénesis |
| KR101999872B1 (ko) | 2011-10-11 | 2019-07-12 | 백시넥스 인코포레이티드 | 혈뇌 장벽 투과성의 조정에 있어서의 세마포린-4d 결합 분자의 용도 |
| US8790652B2 (en) | 2011-12-06 | 2014-07-29 | Vaccinex, Inc. | Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis |
| US9090709B2 (en) * | 2012-03-28 | 2015-07-28 | Vaccinex, Inc. | Anti-SEMA4D antibodies and epitopes |
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| US10494440B2 (en) * | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| JP6611709B2 (ja) | 2013-06-25 | 2019-11-27 | バクシネックス インコーポレーティッド | 腫瘍成長および転移を阻害するための免疫調節療法との組み合わせでのセマフォリン−４ｄ阻害分子の使用 |
| NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
| NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| EP3241844B1 (en) | 2014-12-03 | 2021-04-21 | Aimed Bio Inc. | Antibody against neuropilin 1 and use thereof |
| DK3445397T3 (da) | 2016-04-22 | 2023-02-06 | Vaccinex Inc | Integral membrane protein display on poxvirus extracellular enveloped virions |
| AU2017273170B2 (en) * | 2016-06-03 | 2020-08-27 | Aimed Bio Inc. | Anti-NRP1 antibody screening method |
| JP7128177B2 (ja) | 2016-08-02 | 2022-08-30 | バクシネックス インコーポレーティッド | ワクシニアウイルス／真核細胞においてポリヌクレオチドライブラリを生成するための改善された方法 |
| MX2019011130A (es) | 2017-03-20 | 2019-11-05 | Vaccinex Inc | Tratamiento del cancer con un anticuerpo semaforina-4d en combinacion con un agente de modulacion epigenetica. |
| CN110636858B (zh) | 2017-05-05 | 2024-03-19 | 瓦西尼斯公司 | 人抗脑信号蛋白4d抗体 |
| CA3127474A1 (en) | 2019-03-28 | 2020-10-01 | Vaccinex, Inc. | Semaphorin-4d antagonists for use in cancer therapy |
| EP4007774A1 (en) | 2019-08-01 | 2022-06-08 | Vaccinex, Inc. | Combined inhibition of semaphorin-4d and tgfb and compositions therefor |
| EP4172205A1 (en) | 2020-06-25 | 2023-05-03 | Vaccinex, Inc. | Use of semaphorin-4d binding molecules for the treatment of rett syndrome |
| WO2023048726A1 (en) | 2021-09-27 | 2023-03-30 | Vaccinex, Inc. | Predictive outcome profiling for use of an anti-semaphorin-4d binding molecule to treat neurodegenerative disorders |
| US20230331863A1 (en) | 2022-02-13 | 2023-10-19 | Vaccinex, Inc. | Combination therapy with semaphorin-4d blockade and htt-lowering agent for treatment of huntington's disease |
| CN117866091A (zh) * | 2022-10-12 | 2024-04-12 | 三优生物医药(上海)有限公司 | 抗cd100抗体及其用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2686087A1 (fr) * | 1992-01-13 | 1993-07-16 | Inst Nat Sante Rech Med | Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications. |
| US5639856A (en) | 1993-09-13 | 1997-06-17 | The Regents Of The University Of California | Semaphorin gene family |
| US6576754B2 (en) * | 1995-11-09 | 2003-06-10 | Dana-Farber Cancer Institute | CD100 antigen and uses therefor |
| US6635742B1 (en) * | 2000-01-25 | 2003-10-21 | Nuvelo, Inc. | Antibodies specific for semaphorin-like polypeptides |
| EP1442749A1 (en) * | 2003-01-31 | 2004-08-04 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system |
-
2003
- 2003-01-31 EP EP03290247A patent/EP1442749A1/en not_active Withdrawn
-
2004
- 2004-02-02 BR BR0406689-8A patent/BRPI0406689A/pt not_active Application Discontinuation
- 2004-02-02 WO PCT/EP2004/001743 patent/WO2004067034A1/en active Application Filing
- 2004-02-02 JP JP2006501920A patent/JP4768597B2/ja not_active Expired - Fee Related
- 2004-02-02 SI SI200431917T patent/SI1587542T1/sl unknown
- 2004-02-02 EP EP04707230A patent/EP1587542B1/en not_active Expired - Lifetime
- 2004-02-02 PT PT04707230T patent/PT1587542E/pt unknown
- 2004-02-02 DK DK04707230.1T patent/DK1587542T3/da active
- 2004-02-02 CA CA2514226A patent/CA2514226C/en not_active Expired - Fee Related
- 2004-02-02 US US10/544,031 patent/US8067247B2/en not_active Expired - Fee Related
- 2004-02-02 ES ES04707230T patent/ES2388735T3/es not_active Expired - Lifetime
-
2011
- 2011-10-11 US US13/270,449 patent/US20120027758A1/en not_active Abandoned
-
2012
- 2012-08-07 CY CY20121100707T patent/CY1112953T1/el unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7150286B2 (ja) | 2018-07-19 | 2022-10-11 | 国立大学法人 東京大学 | Ｈｔｌｖ－１関連脊髄症（ｈａｍ）治療又は予防剤、及びｈａｍの治療方法 |
| JP7475011B2 (ja) | 2018-07-19 | 2024-04-26 | 国立大学法人 東京大学 | Ｈｔｌｖ－１関連脊髄症（ｈａｍ）治療又は予防剤、及びｈａｍの治療方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006516594A5 (ja) | ||
| US20230168252A1 (en) | Dectection of exosomes and exosomal biomarkers for the diagnosis and prognosis of diseases and disorders | |
| Bränn et al. | Inflammatory markers in women with postpartum depressive symptoms | |
| Ebbo et al. | Pathologies associated with serum IgG4 elevation | |
| EP2293078B1 (en) | Method for diagnosis of a bacterial infection | |
| Nakashima | Clinical significance of myositis-specific autoantibodies | |
| KR20160068964A (ko) | 알쯔하이머병 및 다른 신경퇴행성 장애에 대한 바이오마커 및 진단 방법 | |
| WO2010038974A3 (ko) | 이뮤노글로블린 에이 신증과 티지비엠 신증의 진단용 조성물 및 키트 | |
| Urushiyama et al. | Role of α1 and α2 chains of type IV collagen in early fibrotic lesions of idiopathic interstitial pneumonias and migration of lung fibroblasts | |
| AU2009320061A1 (en) | Inflammatory bowel disease biomarkers and related methods of treatment | |
| Signorelli et al. | Longitudinal serum biomarker screening identifies malate dehydrogenase 2 as candidate prognostic biomarker for Duchenne muscular dystrophy | |
| Tang et al. | Quantum dots-based sandwich immunoassay for sensitive detection of Alzheimer's disease-related Aβ1–42 | |
| US9983212B2 (en) | In vitro method for the early detection of a potential inflammation, in particular associated with rejection of a transplant, a neurodegenerative disorder or a depression | |
| JP2024037794A (ja) | 神経変性を検出するためのアッセイ | |
| Ichinose et al. | Novel anti-suprabasin antibodies may contribute to the pathogenesis of neuropsychiatric systemic lupus erythematosus | |
| Cysique et al. | The kynurenine pathway relates to post‐acute COVID‐19 objective cognitive impairment and PASC | |
| Rossi et al. | Brief report: antibodies reacting to brain tissue in Basque Spanish children with autism spectrum disorder and their mothers | |
| EP3635409A1 (en) | In vitro method for the determination of neurodegenerative diseases | |
| Wang et al. | Human serum RNase-L level is inversely associated with metabolic syndrome and age | |
| CN103983787A (zh) | 作为神经退行性疾病诊断/预后指示物的谷氨酰胺酰环化酶 | |
| Duan et al. | Seed amplification assay of nasal swab extracts for accurate and non-invasive molecular diagnosis of neurodegenerative diseases | |
| Li et al. | A highly sensitive sandwich ELISA to Detect CSF progranulin: a potential biomarker for CNS disorders | |
| WO2020255938A1 (ja) | 軽度認知障害の診断マーカー | |
| Kapaki et al. | Novel CSF biomarkers tracking autoimmune inflammatory and neurodegenerative aspects of CNS diseases | |
| Halacheva et al. | Elevated anticardiolipin antibodies in schizophrenic patients before and during neuroleptic medication |